These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18781824)

  • 41. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
    Schupp M; Janke J; Clasen R; Unger T; Kintscher U
    Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiotensin receptor blockers in clinical practice--implications of the ONTARGET study.
    Jarvis S
    J Int Med Res; 2012; 40(1):10-7. PubMed ID: 22429341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
    Düsing R; Sellers F
    Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPARγ Activation.
    Elkahloun AG; Rodriguez Y; Alaiyed S; Wenzel E; Saavedra JM
    Mol Neurobiol; 2019 May; 56(5):3193-3210. PubMed ID: 30105672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
    Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
    Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pleiotropic effects of ARB on dyslipidemia.
    Taguchi I; Inoue T; Kikuchi M; Toyoda S; Arikawa T; Abe S; Node K
    Curr Vasc Pharmacol; 2011 Mar; 9(2):129-35. PubMed ID: 21143172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
    Garg J; Bakris GL
    Curr Hypertens Rep; 2002 Jun; 4(3):185-90. PubMed ID: 12003699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.
    Raptis AE; Bacharaki D; Mazioti M; Marathias KP; Markakis KP; Raptis SA; Dimitriadis GD; Vlahakos DV
    Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):416-9. PubMed ID: 22441720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Telmisartan: a different angiotensin II receptor blocker protecting a different population?
    Burnier M
    J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
    Brown NJ; Kumar S; Painter CA; Vaughan DE
    Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
    Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
    Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J; Praga M; de Vinuesa SG
    Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
    Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
    J Hypertens; 2001 Mar; 19(3):465-73. PubMed ID: 11288817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Guthrie R
    Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.